Exploring Precision Medicine in Parkinson’s Disease: New Research and Therapies

Parkinson’s disease (PD) affects more than 10 million people worldwide, with about 90,000 new cases diagnosed annually in the U.S. alone, according to the Parkinson’s Foundation. As the population ages, those numbers are expected to rise, making it more important than ever to find better ways to manage and treat this complex neurological condition.¹ At Private Health Management (PHM), we understand the importance of personalized care, including the use of precision medicine—a cutting-edge method that tailors treatment to each individual’s unique genetic makeup, environment, and lifestyle that is gaining significant traction in improving PD outcomes. This article explores recent advancements in how precision medicine is reshaping the treatment landscape for PD.

What is Parkinson’s Disease?

PD is a progressive, neurodegenerative condition that mainly impacts movement. It is caused by the degeneration of neurons in the brain that produce dopamine—a neurotransmitter that plays a key role in regulating movement, mood, and motivation—leading to reduced dopamine levels and impaired movement control.^2,3 It is characterized by the accumulation of Lewy bodies, which are abnormal clumps of a misfolded protein (α-synuclein) inside nerve cells, which can lead to nerve dysfunction and death⁴.

The main symptoms of PD are movement-related, such as tremors, stiffness, slowed movement (bradykinesia), and balance issues, but the condition also includes non-motor symptoms like cognitive decline, depression, speech and handwriting changes, and sleep disturbances.^2,3 It affects 1–2 per 1,000 people and is more common in men, particularly those over 60 years old.¹ While a small number of PD cases (5–10%) are linked to inherited genetic mutations,^2,5 most are sporadic, influenced by a combination of genetic, environmental, and age-related factors.

While there is currently no cure for PD, a range of treatments can help manage symptoms and improve quality of life. These include medications, physical therapy, lifestyle changes, and in some cases, deep brain stimulation. Motor symptoms are often treated with medications like levodopa (usually combined with carbidopa) to boost dopamine levels, dopamine agonists to mimic dopamine’s effects, and other drugs such as MAO-B inhibitors, COMT inhibitors, and anticholinergics.⁶ However, treatment can be challenging due to side effects like hallucinations and impulse control issues, complex medication schedules, reduced effectiveness over time, and complications from long-term levodopa use, including movement disorders (dyskinesia) and wearing-off effects.⁷

What is precision medicine?

Precision medicine is a modern approach to disease treatment and prevention that tailors medical care to the individual characteristics of each patient, including genetics, biology, environment, and lifestyle. Unlike traditional medicine’s one-size-fits-all model, which often relies on general symptoms and trial-and-error, precision medicine uses tools like genetic testing and biomarkers to guide therapy, predict treatment responses, and focus on prevention.⁸ By developing targeted therapies that are more effective and have fewer side effects, precision medicine offers a more personalized and proactive way to manage health.

Recent advances in precision medicine for Parkinson’s Disease

Recent advances in genetic research have deepened our understanding of PD, revealing specific gene mutations, such as those in the LRRK2 and GBA1 genes, that are linked to distinct subtypes of the condition.⁹ Identifying these genetic markers allows for earlier diagnosis, more accurate predictions of disease progression, and the development of treatments tailored to a person’s unique genetic profile. This approach helps doctors go beyond treating symptoms, focusing instead on the underlying biological mechanisms. For instance, a patient with a GBA1 mutation may benefit from therapies that enhance enzyme function, while someone with a LRRK2 mutation might respond better to a different targeted treatment.

Biomarkers have also emerged as critical tools in precision medicine, offering ways to diagnose PD at earlier stages—even before noticeable symptoms occur.⁹ Researchers are currently developing imaging techniques, blood tests, and spinal fluid analyses that may reliably identify these biomarkers, potentially allowing interventions when they might be most effective.

Emerging precision therapies and clinical trials

Emerging precision therapies for PD focus on individualized approaches to improving treatment outcomes, slowing disease progression and enhancing quality of life. Ongoing research and clinical trials are crucial to determine their long-term efficacy and safety. Some key areas of advancement include:

Gene therapy and targeted treatments:¹⁰

• LRRK2 Inhibitors: Some people with PD have mutations in the LRRK2 gene. Scientists are testing drugs that block this gene’s activity, which could help slow down disease progression. Clinical trials are underway.¹¹​
• GBA1-Directed Therapies: Mutations in the GBA1 gene can raise the risk of developing PD. Treatments designed to boost the activity of a helpful enzyme (glucocerebrosidase) are being studied to target this risk.​
• Gene Therapy Approaches: In one promising trial, researchers used a harmless virus to deliver a therapeutic gene (AAV-GAD) into the brain. This gene boosts production of GABA, a calming brain chemical that helps balance brain activity and ease motor symptoms. Patients who received the highest dose had significant improvements in quality of life after 26 weeks, suggesting gene therapy could play a role in controlling symptoms long-term.

Stem cell research and regenerative medicine:

• Dopaminergic Neuron Patient-Specific Stem Cell Therapies: Researchers are using a patient’s own cells to grow new dopamine-producing neurons—the type that PD affects. These lab-grown cells could be transplanted into the brain to restore lost function. Clinical trials are evaluating the safety and effectiveness of these approaches.^12,13 ​

Personalized drug treatments and repurposing existing medications:

• Monoclonal Antibody Treatments: A new drug called prasinezumab is designed to target a protein called alpha-synuclein, which may play a key role in PD. Early results suggest it might slow down progression of movement-related symptoms in rapidly progressing, early-stage PD.¹⁴
• Drug Repurposing: Researchers are exploring whether familiar medications can be used in new ways. One example is ambroxol, a common cough medicine, now being tested to see if it can slow Parkinson’s progression. A major clinical trial in the UK is tracking over 300 patients to find out.

Overall, personalized treatment approaches guided by genetic and molecular profiling represent an encouraging shift in PD care. By precisely targeting the biological pathways involved in an individual’s disease, these personalized strategies promise greater therapeutic success and fewer side effects.

References

1. Prevalence & Incidence | Parkinson’s Foundation. https://www.parkinson.org/understanding-parkinsons/statistics/prevalence-incidence.
2. Balestrino, R. & Schapira, A. H. V. Parkinson disease. Eur J Neurol 27, 27–42 (2020).
3. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).
4. Leak, R. K. et al. Current insights and assumptions on α-synuclein in Lewy body disease. Acta Neuropathol 148, 18 (2024).
5. Tran, J., Anastacio, H. & Bardy, C. Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells. npj Parkinsons Dis. 6, 1–18 (2020).
6. Yuan, H. et al. Treatment strategies for Parkinson’s disease. Neurosci. Bull. 26, 66–76 (2010).
7. Jones, S., Patel, J. P., Twigg, M. J. & Chaudhuri, K. R. What is known about the challenges people with Parkinson’s disease experience with their medicines and what solutions have been explored to overcome them? A scoping review. International Journal of Pharmacy Practice 32, 431–445 (2024).
8. Drugan, T. & Leucuța, D. Evaluating Novel Biomarkers for Personalized Medicine. Diagnostics 14, 587 (2024).
9. Bougea, A. Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomedicines 12, 549 (2024).
10. Serva, S. N., Bernstein, J., Thompson, J. A., Kern, D. S. & Ojemann, S. G. An update on advanced therapies for Parkinson’s disease: From gene therapy to neuromodulation. Front. Surg. 9, (2022).
11. Elkouzi, A., Vedam-Mai, V., Eisinger, R. S. & Okun, M. S. Emerging therapies in Parkinson disease — repurposed drugs and new approaches. Nat Rev Neurol 15, 204–223 (2019).
12. Schweitzer, J. S. et al. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson’s Disease. N Engl J Med 382, 1926–1932 (2020).
13. Stoddard-Bennett, T. & Reijo Pera, R. Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells 8, 26 (2019).
14. Pagano, G. et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nat Med 30, 1096–1103 (2024).